QC
CCCC icon

Quadrature Capital’s C4 Therapeutics CCCC Stock Holding History

Quadrature Capital’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$172K Sell
36,726
-26,034
-41% -$89K ﹤0.01% 1387
2026
Q1 		$165K Sell
62,760
-70,352
-53% -$166K ﹤0.01% 1158
2025
Q4 		$254K Buy
+133,112
New +$315K ﹤0.01% 900
2025
Q3 		– Sell
-13,547
Closed -$19.3K – 1089
2025
Q2 		$19.3K Sell
13,547
-2,462
-15% -$3.58K ﹤0.01% 992
2025
Q1 		$25.5K Buy
+16,009
New +$47.8K ﹤0.01% 1021

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Quadrature Capital's CCCC Position: Q2 2026 in Review

Quadrature Capital reduced its C4 Therapeutics (CCCC) stake by 41% in Q2 2026, selling an estimated $89K and leaving 36,726 shares worth $172K. The position accounts for ﹤0.01% of the portfolio, ranked #1387.

Quadrature Capital first reported a position in CCCC in Q1 2025 and has held it in 5 quarters since. The position peaked at $254K in Q4 2025. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Quadrature Capital held 36,726 shares of C4 Therapeutics worth $172K as of Q2 2026.
  • Quadrature Capital sold 26,034 C4 Therapeutics shares in Q2 2026, an estimated $89K.
  • C4 Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1387 holding.
  • Quadrature Capital first reported a position in C4 Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Quadrature Capital's C4 Therapeutics position peaked at $254K in Q4 2025.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.